Key Statistics
12
Markets analysed
US · EU5 · UK · JP · AU · CA
42%
Median gross-to-net discount
US immunology biologics (2025)
80+
Immunology products tracked
TNF-α, IL inhibitors, JAKi, B-cell depleting
$220B
Global immunology market 2026
CAGR ~8% driven by biosimilar erosion
65%
Price premium for clinical differentiation
Vs. competitor product in same class
18mo
Median time to net price stability
Post-launch rebate negotiation period
Target Profile
| Drug Classes in Scope | TNF-α inhibitors · IL-4/13 inhibitors · IL-17/23 inhibitors · JAK inhibitors · B-cell depleting agents (CD20, BAFF) · Complement inhibitors · S1P modulators |
|---|---|
| Key Markets | United States (Part D / commercial / Medicaid)Germany (GKV / AMNOG)France (HAS / CEPS)UK (NHS England / NICE)Japan (MHLW / CHUIKYO)Australia (PBS / PBAC)Canada (CADTH / pCPA) |
| Gross-to-Net Drivers (US) | PBM formulary placement rebatesMedicaid best-price obligations340B discountsIRA negotiation exposureBiosimilar erosion pressure |
| Key Finding | Products with a clinically distinct mechanism (IL-23 inhibitors vs. IL-17) command 35–65% net price premiums over class competitors. Head-to-head trial data is now a near-prerequisite for premium pricing in EU5 markets. |
12TNF-α inhibitors
18IL inhibitors (17/23/4/13)
8JAK inhibitors
10B-cell agents
16Emerging classes
20Biosimilars (key products)
Drug Landscape
| Drug Name | Company | Modality | Indication | Stage | Mechanism |
| Dupilumab (Dupixent) | Sanofi / Regeneron | mAb (IL-4Rα) | AD, Asthma, CRSwNP | Price leader | Net price premium sustained across EU5 — clinical differentiation via H2H data |
| Risankizumab (Skyrizi) | AbbVie | mAb (IL-23p19) | Psoriasis, PsA, CD, UC | Strong access | IL-23 selectivity + H2H vs. secukinumab driving premium in EU markets |
| Upadacitinib (Rinvoq) | AbbVie | JAKi (JAK1) | RA, AD, PsA, AS, CD, UC | Access risk | JAK safety label restricts access in EU — black box limits formulary position |
| 🔒 Full Net Price Model | 80+ products | — | All immunology classes | Locked | Per-product net price estimates in paid report |
| 🔒 12-Market Comparison Table | All markets | — | All products | Locked | Cross-market pricing data in paid report |
#Immunology#DrugPricing#MarketAccess#NetPricing#HTA#Biosimilars#PharmaPolicy#Reimbursement#PricingStrategy#IRANegotiation#GlobalPharma#HealthEconomics#HEOR